Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
This article was originally published in PharmAsia News
Executive Summary
Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.
Topics
- Industries
- BioPharmaceutical
- Regions
- Asia Pacific
- Subjects
- Deals
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC079357
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC079357
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.